ReviewNeurologic clinics2014
Idiopathic inflammatory myopathies.
Review in Neurologic clinics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Meta-Analysis of Polymyositis and Dermatomyositis Microarray Data Reveals Novel Genetic Biomarkers.Genes · 2019Pooled it
- From myositis to sarcoidosis: a rare autoimmune continuum.EULAR rheumatology open · 2026Article
- Whole-body magnetic resonance imaging in rheumatology: advancements, key applications and future perspectives.La Radiologia medica · 2026Review
- Dermatomyositis: Prevalence, Clinical Spectrum, Diagnostic Approach, and Management Strategies.Archives of internal medicine research · 2026Article
- "I Can't Lift My Legs": An Interesting Presentation Leading to the Diagnosis of Anti-synthetase Syndrome.Cureus · 2025Article
- Polymorphisms ofReumatologia · 2025Article
- Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.Clinical rheumatology · 2023Article
- Dermatomyositis Flare-Up Following the SARS-CoV-2 Vaccine: A Case Report and Literature Review.Cureus · 2023Article
- Article
- Sarcoplasmic Myxovirus Resistance Protein A: A Study of Expression in Idiopathic Inflammatory Myopathy.Journal of inflammation research · 2023Article
- Renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the MyoCite cohort.Frontiers in medicine · 2023Article
- Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination.Journal of Korean medical science · 2022Article
- Clinical, Serological, and Genetic Characteristics of a Hungarian Myositis-Scleroderma Overlap Cohort.BioMed research international · 2022Article
- Real world utilization of the myositis autoantibody panel.Clinical rheumatology · 2021Article
- Therapeutic management of immune-mediated necrotizing myositis.Current treatment options in rheumatology · 2021Article
- Vaccination as a possible trigger for immune-mediated necrotising myopathy.BMJ case reports · 2021Article
- Utilization of myositis antibody-specific panel for diagnosis, treatment, and evaluation of disease progression.Journal of community hospital internal medicine perspectives · 2020Article
- Analysis of myositis autoantibodies in Chinese patients with cancer-associated myositis.Journal of clinical laboratory analysis · 2020Article
- Patient-Reported Outcomes in Adult Idiopathic Inflammatory Myopathies.Current rheumatology reports · 2019Review
- The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.Clinical rheumatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The idiopathic inflammatory myopathies (IIM) consist of rare heterogeneous autoimmune disorders that present with marked proximal and symmetric muscle weakness, except for distal and asymmetric weakness in inclusion body myositis. Despite many similarities, the IIM are fairly heterogeneous from the histopathologic and pathogenetic standpoints, and also show some clinical and treatment-response differences. The field has witnessed significant advances in our understanding of the pathophysiology and treatment of these rare disorders. This review focuses on dermatomyositis, polymyositis, and necrotizing myopathy, and examines current and promising therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.